| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Authors’ reply to Schaffalitzky de Muckadell and colleague’s Comment on “Evaluation of the Reported Rates of Severe Hypersensitivity Reactions Associated with Ferric Carboxymaltose and Iron (III) Isomaltoside 1000 in Europe Based on Data from EudraVigilance and VigiBase™ between 2014 and 2017”
|
Ehlken, Birgit
|
|
2019
|
42 |
5 |
p. 693-696
|
article
|
| 2 |
Benefit–Risk Assessment of Blinatumomab in the Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
|
Stein, Anthony
|
|
2018
|
42 |
5 |
p. 587-601
|
article
|
| 3 |
Benefit–Risk Assessment of Plecanatide in the Treatment of Chronic Idiopathic Constipation
|
Miner, Philip B.
|
|
2019
|
42 |
5 |
p. 603-615
|
article
|
| 4 |
Benefit–Risk Assessment of Vedolizumab in the Treatment of Crohn’s Disease and Ulcerative Colitis
|
Battat, Robert
|
|
2019
|
42 |
5 |
p. 617-632
|
article
|
| 5 |
Building an Evidence Base on the Place of Industry-Sponsored Programs in Drug Safety Surveillance
|
Arlett, Peter
|
|
2019
|
42 |
5 |
p. 581-582
|
article
|
| 6 |
Comment on ‘Evaluation of the Reported Rates of Severe Hypersensitivity Reactions Associated with Ferric Carboxymaltose and Iron(III) Isomaltoside 1000 in Europe Based on Data from EudraVigilance and VigiBase™ Between 2014 and 2017’
|
Schaffalitzky de Muckadell, Philip
|
|
|
42 |
5 |
p. 689-691
|
article
|
| 7 |
Correction to: Antipsychotic Prescribing to Patients Diagnosed with Dementia Without a Diagnosis of Psychosis in the Context of National Guidance and Drug Safety Warnings: Longitudinal Study in UK General Practice
|
Stocks, S. Jill
|
|
2019
|
42 |
5 |
p. 697
|
article
|
| 8 |
Development of a Controlled Vocabulary-Based Adverse Drug Reaction Signal Dictionary for Multicenter Electronic Health Record-Based Pharmacovigilance
|
Lee, Suehyun
|
|
2019
|
42 |
5 |
p. 657-670
|
article
|
| 9 |
Drug-Induced Anaphylaxis in a Vietnamese Pharmacovigilance Database: Trends and Specific Signals from a Disproportionality Analysis
|
Nguyen, Khac-Dung
|
|
2018
|
42 |
5 |
p. 671-682
|
article
|
| 10 |
Evaluation of Postmarketing Reports from Industry-Sponsored Programs in Drug Safety Surveillance
|
Harinstein, Lisa
|
|
2018
|
42 |
5 |
p. 649-655
|
article
|
| 11 |
From Data Silos to Standardized, Linked, and FAIR Data for Pharmacovigilance: Current Advances and Challenges with Observational Healthcare Data
|
Koutkias, Vassilis
|
|
2019
|
42 |
5 |
p. 583-586
|
article
|
| 12 |
Managing Risks with Immune Therapies in Multiple Sclerosis
|
Förster, Moritz
|
|
2019
|
42 |
5 |
p. 633-647
|
article
|
| 13 |
Workshop on the Italian Pharmacovigilance System in the International Context: Critical Issues and Perspectives
|
Sultana, Janet
|
|
2018
|
42 |
5 |
p. 683-687
|
article
|
Journal description